Low MOQ for Sodium Acetate Pubchem - Other Protected Amino Acids for Disulfide bond – Gentolex
Low MOQ for Sodium Acetate Pubchem - Other Protected Amino Acids for Disulfide bond – Gentolex Detail:
Product Detail
|
NO |
Products |
CAS No |
Application |
Key Quality Indicator |
||||
|
Purity |
Isomer |
Specific impurity |
*Max1 |
Moisture |
||||
|
1 |
Fmoc-Cys(Acm)-OH |
86060-81-3 |
Disulfide bond |
≥99.0% |
≤0.1% |
≤0.1% |
≤0.2% |
≤1.0% |
|
2 |
Fmoc-Cys(Mmt)-OH |
177582-21-7 |
Disulfide bond |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
3 |
Fmoc-Cys(4-allylbutyrate)-OH |
/ |
Disulfide bond |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
4 |
Mpa(Trt)-OH |
27144-18-9 |
End of sequence |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
5 |
Fmoc-Thr(tBu)-OL |
189337-28-8 |
Octreotide |
≥97.0% |
≤0.3% |
≤0.5% |
≤1.0% |
≤1.0% |
|
6 |
Fmoc-D-Arg(pbf)-OH |
187618-60-6 |
Desmopressin |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤2.0% |
|
7 |
Fmoc-Gly-Gly-OH |
35665-38-4 |
Bivalirudin |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
8 |
Fmoc-Gly-Gly-Gly-OH |
170941-79-4 |
Terlipressin |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
9 |
Fmoc-Gly-Gly-Gly-Gly-OH |
/ |
Bivalirudin |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
10 |
Fmoc-Gly-Asp(tBu)-OH |
/ |
Bivalirudin |
≥99.5% |
/ |
≤0.15% |
≤0.2% |
≤1.0% |
|
11 |
Boc-Cys(Trt)-OH |
21947-98-8 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
12 |
Boc-Arg(pbf)-OH |
200124-22-7 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
13 |
Boc-Ala-OH |
15761-38-3 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
14 |
Boc-D-Phe-OH |
18942-49-9 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
15 |
Boc-Gly-OH |
4530-20-5 |
End of sequence |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
16 |
Boc-Lys(Boc)-OH.DCHA |
15098-69-8 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
17 |
Boc-Ser(tBu)-OH |
7738-22-9 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
18 |
Boc-Thr(tBu)-OH |
13734-40-2 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
19 |
Boc-D-Ala-OH |
7764-95-6 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
20 |
Boc-Met-OH |
2488-15-5 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
21 |
Boc-Tyr(tBu)-OH |
47375-34-8 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
22 |
Boc-D-Arg(pdf)-OH |
187618-60-6 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
23 |
Boc-Asp(OtBu)-OH.DCHA |
1913/12/8 |
End of sequence |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
24 |
Fmoc-HomoArg(pbf)-OH |
1159680-21-3 |
Eptifibatide |
≥98.5% |
≤0.2% |
/ |
≤0.5% |
≤2.0% |
|
25 |
Fmoc-Asp-OtBu |
129460-09-9 |
Thymalfasin |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤1.0% |
|
26 |
Fmoc-Tyr(Me)-OH |
77128-72-4 |
Carbetocin |
≥98.5% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
27 |
Fmoc-Orn(Boc)-OH |
109425-55-0 |
Atosiban Omnipressin Daptomycin |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤2.0% |
|
28 |
Fmoc-D-Tyr(Et)-OH |
162502-65-0 |
Atosiban |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤1.0% |
|
29 |
Fmoc-Asp(OAll)-OH |
146982-24-3 |
Melanotan |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
30 |
Ac-Nle-OH |
15891-49-3 |
Melanotan |
≥99.0% |
/ |
≤0.3% |
≤0.3% |
≤1.0% |
|
31 |
Fmoc-Nle-OH |
77284-32-3 |
Melanotan Afamelanotide |
≥99.0% |
/ |
≤0.3% |
≤0.3% |
≤1.0% |
|
32 |
Ac-Glu(OtBu)-OH |
84192-88-1 |
Argireline Acetyl octapeptide-3 |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
33 |
Ac-β-Ala-OH·DCHA |
/ |
Acetyl tetrapeptide-5 |
≥99.0% |
/ |
≤0.3% |
≤0.3% |
≤1.0% |
|
34 |
Fmoc-ß-Ala-OH |
35737-10-1 |
Acetyl tetrapeptide-5 |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
35 |
Fmoc-Hyp(tBu)-OH |
122996-47-8 |
Icatibant |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
36 |
Fmoc-Thi-OH |
130309-35-2 |
Icatibant |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
37 |
Fmoc-D-Tic-OH |
130309-33-0 |
Icatibant |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
38 |
Fmoc-Oic-OH |
130309-37-4 |
Icatibant |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
39 |
Boc-Sar-OH |
13734-36-6 |
Saralasin |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
40 |
Fmoc-Sar-OH |
77128-70-2 |
Saralasin |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
41 |
Fmoc-Tyr(SO3Na)-OH.H2O |
106864-37-3 |
Sincalide |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
42 |
Fmoc-D-Asp(OtBu)-OH |
112883-39-3 |
Daptomycin |
≥98.5% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
43 |
Ac-Ser(tBu)-OH |
77285-09-7 |
Afamelanotide |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
|
44 |
Boc-HomoCys(Trt)-OH |
201419-16-1 |
Depreotide |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
45 |
Fmoc-HomoCys(Trt)-OH |
167015-23-8 |
Depreotide |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
46 |
Fmoc-Dab-OH |
161420-87-7 |
Snake venom |
≥99.0% |
≤0.2% |
≤0.3% |
≤0.3% |
≤1.0% |
*Max1 = Max Unknown Purity
Other Indicator:
- Acetic Acid: ≤0.02% (All Products)
- Ethyl Acetate: ≤0.5% (All Products)
- Alcohol: ≤0.5% (All Products)
- Max Unknow Impurity: Fmoc-Trp(Boc)-OH (143824-78-6) ≤0.3%; Others ≤0.2%
Product detail pictures:
Related Product Guide:
We will devote ourselves to giving our esteemed buyers using the most enthusiastically thoughtful services for Low MOQ for Sodium Acetate Pubchem - Other Protected Amino Acids for Disulfide bond – Gentolex , The product will supply to all over the world, such as: Russia, Nigeria, Panama, Be sure to feel cost-free to send us your specs and we are going to respond for you asap. We have got a experienced engineering team to serve for the every single comprehensive needs. Free samples may be sent for yourself personally to know far more facts. So that you can meet your desires, please actually feel cost-free to contact us. You could send us emails and call us straight. Additionally, we welcome visits to our factory from all over the world for much better recognizing of our corporation. nd merchandise. In our trade with merchants of several countries, we often adhere to the principle of equality and mutual advantage. It is our hope to market, by joint efforts, both trade and friendship to our mutual benefit. We look forward to getting your inquiries.
By Edward from Mauritius - 2018.02.21 12:14
Managers are visionary, they have the idea of "mutual benefits, continuous improvement and innovation", we have a pleasant conversation and Cooperation.
By Roxanne from kazakhstan - 2017.08.21 14:13
